At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 509 enrolled
Drug / intervention
CP-690,550 +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
In Brief
A Phase 2 clinical trial evaluating CP-690,550 and placebo for Arthritis, Rheumatoid. Completed, enrolled 509 participants across 82 sites in 13 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesArgentina, Brazil, Bulgaria, Chile, Czechia, Hungary, Mexico, Poland, Slovakia, Spain, Sweden, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedDec 20, 2006
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.5 years ago
Interventions
CP-690,550drug
4 blinded tablets administered BID
CP-690,550drug
4 blinded tablets administered BID
CP-690,550drug
4 blinded tablets administered BID
CP-690,550drug
4 blinded tablets administered BID
CP-690,550drug
4 blinded tablets administered BID
CP-690,550drug
Oral tablets
placeboother
Placebo